| | Need more clues to decide? Try these (from PubMed) ...
=========================
An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med. 1990 Aug 9;323(6):357-65.
Division of Field Services, Centers for Disease Control, Minneapolis, MN.
... CONCLUSIONS. The outbreak of the eosinophilia-myalgia syndrome in 1989 resulted from the ingestion of a chemical constituent that was associated with specific tryptophan-manufacturing conditions at one company. The chemical constituent represented by peak E may contribute to the pathogenesis of the eosinophilia-myalgia syndrome, or it may be a surrogate for another chemical that induces the syndrome.
=========================
... and, over a decade later ...
=========================
Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs. 2004;18(7):453-68.
Departments of Obstetrics/Gynecology and Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
... Symptom reduction with tryptophan was significantly greater than with placebo, but the availability of this medication is strictly limited because of safety concerns. ... =========================
Even over a decade after the discovery of the contamination of tryptophan as the cause of EMS, the availibility of this tryptophan was "strictly limited because of safety concerns." [??]
Yeah, right. Tell me, have there ever been any other products -- e.g., Perrier, Tylenol, etc -- which were held off of the market for over a decade (in this case, the expiration time of the patent for a drug which competes with it) AFTER THEY had been found to be contaminated?
No answer? Hmm ... interesting train of events.
Ed
|
|
